Patents by Inventor Lex M. Cowsert

Lex M. Cowsert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6294382
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SRC-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SRC-1. Methods of using these compounds for modulation of SRC-1 expression and for treatment of diseases associated with expression of SRC-1 are provided.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: September 25, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6284538
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTEN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTEN. Methods of using these compounds for modulation of PTEN expression and for treatment of diseases and conditions associated with expression of PTEN are provided. Such conditions include diabetes and hyperproliferative conditions. Methods for decreasing blood glucose levels, inhibiting PEPCK expression, decreasing blood insulin levels, decreasing insulin resistance, increasing insulin sensitivity, decreasing blood triglyceride levels or decreasing blood cholesterol levels in an animal using the compounds of the invention are also provided. The animal is preferably a human; also preferably the animal is a diabetic animal.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: September 4, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert, Robert McKay
  • Publication number: 20010016575
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions include antisense compounds targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.
    Type: Application
    Filed: January 2, 2001
    Publication date: August 23, 2001
    Inventors: Loren J. Miraglia, Pamela Nero, Mark J. Graham, Brett P. Monia, Lex M. Cowsert
  • Patent number: 6277640
    Abstract: Antisense compounds, compositions and methods are provided for inhibiting the expression of Her-3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Her-3. Methods of using these compounds for inhibition of Her-3 expression and for treatment of diseases associated with expression of Her-3 are provided.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: August 21, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6277636
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MADH6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MADH6. Methods of using these compounds for modulation of MADH6 expression and for treatment of diseases associated with expression of MADH6 are provided.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: August 21, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Patent number: 6271029
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cytohesin-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cytohesin-2. Methods of using these compounds for modulation of cytohesin-2 expression and for treatment of diseases associated with expression of cytohesin-2 are provided.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: August 7, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6268151
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Macrophage migration inhibitory factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Macrophage migration inhibitory factor. Methods of using these compounds for modulation of Macrophage migration inhibitory factor expression and for treatment of diseases associated with expression of Macrophage migration inhibitory factor are provided.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: July 31, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan Murray, Lex M. Cowsert, Jacqueline Wyatt
  • Patent number: 6261840
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: July 17, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Lex M. Cowsert, Jacqueline Wyatt
  • Patent number: 6258600
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of caspase 8. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding caspase 8. Methods of using these compounds for modulation of caspase 8 expression and for treatment of diseases associated with expression of caspase 8 are provided.
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: July 10, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Hong Zhang, Lex M. Cowsert
  • Patent number: 6258601
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of ubiquitin protein ligases WWP1 and WWP2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ubiquitin protein ligases WWP1 and WWP2. Methods of using these compounds for modulation of ubiquitin protein ligases WWP1 and WWP2 expression and for treatment of diseases associated with expression of ubiquitin protein ligases WWP1 and WWP2 are provided.
    Type: Grant
    Filed: September 7, 2000
    Date of Patent: July 10, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Patent number: 6258790
    Abstract: Compositions and methods are provided for modulating the expression of integrin &agr;4. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding integrin &agr;4 are preferred. Methods of using these compounds for modulating integrin &agr;4 expression and for treatment of diseases associated with expression of integrin &agr;4 are also provided.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: July 10, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Thomas P. Condon, Lex M. Cowsert
  • Patent number: 6255111
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Her-4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Her-4. Methods of using these compounds for modulation of Her-4 expression and for treatment of diseases associated with expression of Her-4 are provided.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: July 3, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6255110
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of ARA70. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ARA70. Methods of using these compounds for modulation of ARA70 expression and for treatment of diseases associated with expression of ARA70 are provided.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: July 3, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Lex M. Cowsert, Jacqueline Wyatt
  • Patent number: 6248586
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PKA catalytic subunit C-alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PKA catalytic subunit C-alpha. Methods of using these compounds for modulation of PKA catalytic subunit C-alpha expression and for treatment of diseases associated with expression of PKA catalytic subunit C-alpha are provided.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: June 19, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Patent number: 6242590
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of zinc finger protein-217. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding zinc finger protein-217. Methods of using these compounds for modulation of zinc finger protein-217 expression and for treatment of diseases associated with expression of zinc finger protein-217 are provided.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: June 5, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Lex M. Cowsert
  • Patent number: 6200807
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SHP-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SHP-2. Methods of using these compounds for modulation of SHP-2 expression and for treatment of diseases associated with expression of SHP-2 are provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: March 13, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6197584
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD40. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40. Methods of using these compounds for modulation of CD40 expression and for treatment of diseases associated with CD40 are provided.
    Type: Grant
    Filed: May 1, 1998
    Date of Patent: March 6, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6190869
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Protein kinase C-theta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Protein kinase C-theta. Methods of using these compounds for modulation of Protein kinase C-theta expression and for treatment of diseases associated with expression of Protein kinase C-theta are provided.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: February 20, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Patent number: 6187587
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 1. Methods of using these compounds for modulation of E2F transcription factor 1 expression and for treatment of diseases associated with expression of E2F transcription factor 1 are provided.
    Type: Grant
    Filed: March 2, 2000
    Date of Patent: February 13, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Ian Popoff, Vickie L. Brown-Driver, Lex M. Cowsert
  • Patent number: 6187545
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PEPCK-cytosolic. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PEPCK-cytosolic. Methods of using these compounds for modulation of PEPCK-cytosolic expression and for treatment of diseases associated with expression of PEPCK-cytosolic are provided.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: February 13, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Madeline M. Butler, Jacqueline Wyatt, Lex M. Cowsert